Update: Immunsuppression bei Organtransplantationen

Georgios Polychronidis; Philipp Houben; Markus Mieth; Christian Morath; Daniel N. Gotthardt; Peter Schemmer

doi:10.1055/s-0042-100573

Allgemein- und Viszeralchirurgie up2date, Inhaltsverzeichnis

Intensivmedizin up2date 2016; 10(01): 23-32
DOI: 10.1055/s-0042-100573

Viszerale Transplantationen

Georg Thieme Verlag KG Stuttgart · New York

Update: Immunsuppression bei Organtransplantationen

Georgios Polychronidis

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg

,

Philipp Houben

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg

,

Markus Mieth

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg

,

Christian Morath

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg

,

Daniel N. Gotthardt

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg

,

Peter Schemmer

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Um eine Transplantatabstoßung zu vermeiden, ist nach Organtransplantation eine Immunsuppression unumgänglich – jedoch mit teils erheblichen Nebenwirkungen. Eine Kombinationstherapie kann die Nebenwirkungen begrenzen, ohne das Transplantat zu gefährden.

Volltext

Referenzen

Literatur
1 Houben P, Gotthardt DN, Radeleff B et al. Complication management after liver transplantation: Increasing patient safety by standardized approach and interdisciplinary cooperation. Chirurg 2015; PMID: 25604306
2 Starzl TE, Groth CG, Brettschneider L et al. Orthotopic homotransplantation of the human liver. Ann Surg 1968; 168: 392-415
3 Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005; 18: 511-519
4 Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58: 452-463
5 Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int 2013; 26: 673-683
6 Mangus RS, Fridell JA, Vianna RM et al. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786-795
7 Gotthardt DN, Bruns H, Weiss KH et al. Current strategies for immunosuppression following liver transplantation. Langenbeckʼs Arch Surg 2014; 399: 981-988
8 Préville X, Flacher M, LeMauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460
9 Xing T, Huang L, Yu Z et al. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 2013; 8: e71251
10 Verna EC, Farrand ED, Elnaggar AS et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplant 2011; 91: 1254-1260
11 Ramirez CB, Doria C, Frank AM et al. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 2013; 27: 463-471
12 De Simone P, Nevens F, De Carlis L et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020
13 Saliba F, De Simone P, Nevens F et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745
14 Fischer L, Klempnauer J, Beckebaum S et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation (PROTECT). Am J Transplant 2012; 12: 1855-1865
15 Sterneck M, Kaiser GM, Heyne N et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14: 701-710
16 Rodriguez-Peralvarez M, Manousou P, Lerut J et al. How much immunosuppression is needed after liver transplantation?. Clin Transplant 2014; 28: 6-7
17 Kidney Disease : Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J of Transplant 2009; 9 (Suppl. 03) S1-S155
18 Préville X, Flacher M, LeMauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460
19 Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465
20 Tydén G, Ekberg H, Tufveson G et al. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012; 94: e21
21 Morath C, Süsal C. Transplantation: rituximab induction only for sensitized kidney recipients?. Nat Rev Nephrol 2013; 9: 703-705
22 Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166
23 Wiland AM, Fink JC, Weir MR et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004; 77: 422
24 Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967
25 Hardinger KL, Brennan DC, Schnitzler MA. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. Transplantation 2009; 87: 1372
26 Miller JT, Collins CD, Stuckey LJ et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009; 29: 1166
27 Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9: 409
28 Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810
29 Atkison P, Joubert G, Barron A et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345: 894
30 Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38 (Suppl. 06) S25
31 Ekberg H, Tedesco-Silva H et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
32 Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535
33 Masson P, Henderson L, Chapman JR et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014;
34 Pascual J, Zamora J, Galeano C et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009;
35 Montero N, Webster AC, Royuela A et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev 2014;
36 Webb NJ, Douglas SE, Rajai A et al. Corticosteroid-Free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. Transplantation 2014; 99: 1178-1185
37 Woodside KJ, Schirm ZW, Noon KA et al. Fever, infection, and rejection after kidney transplant failure. Transplantation 2014; 97: 648-653
38 Augustine JJ, Woodside KJ, Padiyar A et al. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94: 738-743
39 Del Bello A, Congy-Jolivet N, Sallusto F et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7: 1310
40 Shapiro R, Carroll PB, Tzakis AG et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49: 1011
41 Ratcliffe PJ, Dudley CR, Higgins RM et al. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643
42 Andrews PAStandards Committee of the British Transplantation Society. Summary of the British Transplantation Society Guidelines for management of the failing kidney transplant. Transplantation 2014; 98: 1130
43 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. 2015 Im Internet: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015/report/1